Introduction
Vancomycin belongs to the glycopeptide class of antibiotics, which are effective against gram-positive organisms. In contrast, gram-negative bacteria are intrinsically resistant to glycopeptides because of their impermeable outer membrane. Glycopeptides are composed of a heptapeptide backbone that is substituted with five to seven aromatic rings and different sugars. Vancomycin contains two hexoses and five aromatic rings; chloroeremomycin has an additional sugar molecule (Figure 1a,b) . A second glycopeptide antibiotic approved for human use, teicoplanin, contains three sugars and seven aromatic rings ( Figure 1c ).
In contrast to penicillin, which directly binds to and inhibits the bifunctional transglycosylases/transpeptidases involved in cell-wall biosynthesis, vancomycin binds to the substrate of these enzymes, the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the lipid-PP-disaccharide-pentapeptide ( Figure 2a ). Binding of vancomycin to this target is thought to sterically prevent the subsequent action of both activities of the transglycosylase/transpeptidase: adding disaccharyl pentapeptide units to the growing peptidoglycan (PG) strand and then cross-linking peptides within and between PG strands on the external face of the cytoplasmic membrane ( Figure 2b ). This failure to form cross-links between peptidoglycan intermediates lowers the rigidity of the cell wall and renders these bacteria susceptible to osmotic lysis [1] [2] [3] [4] [5] .
During the past decade, vancomycin has become the front-line therapy for treating problematic infections caused by methicillin-resistant Staphylococcus aureus (MRSA), and by enterococci in patients after surgery. The specter of vancomycin-resistant MRSA looms [6] [7] [8] [9] , whereas vancomycin-resistant enterococci (VRE), which cause high mortality rates, have become a distressingly common reality in hospital settings [10, 11] . Three VRE phenotypes have been designated VanA, VanB and VanC on the basis of the minimal inhibitory concentration (MIC) in VRE and susceptibility to teicoplanin (Table 1) [3, 11] . The VanA and VanB phenotypes differ in that VanA is resistant to teicoplanin, whereas VanB is not resistant because the VanB resistance pathway is not activated by teicoplanin (MIC ≤ 0.5 µg/ml) [3] . Both 
, and thus is less able to sterically block the transpeptidation and transglycosylation steps necessary for the formation of the peptidoglycan cell wall [12] .
In contrast to the VanA and VanB phenotypes, VanC resistance in Enterococcus gallinarum and E. casseliflavus is chromosomal, and has only been detected in a few clinical isolates [11, 13] . VanC resistance has a VanC D-alanyl-D-serine (D-Ala-D-Ser) ligase in place of the D-Ala-D-Lac ligases (VanA and VanB). The hydroxymethyl sidechain of D-serine is thought to disrupt sterically the optimal geometry for vancomycin binding to the usual D-Ala-D-Ala termini, resulting in about a sixfold decrease in affinity for vancomycin [14] and a corresponding eightfold increase in the MIC for vancomycin (Table 1) [11] . VanD [15] and VanE [16] [17] . Many of the residues shown by site-directed mutagenesis [18] and structural studies [19] to be important for substrate binding and catalysis by the Escherichia coli D-Ala-D-Ala ligase (DdlB) are highly conserved among the entire Ddl superfamily. The D-Ala-D-Ala and D-Ala-D-Ser ligase (VanC) families also have similar sequences for the projected omega loop that closes over the active site of DdlB and the loop contains Lys215 and Tyr216 (DdlB numbering), which are important for catalysis (discussed further in the next section) [17, 18, 20] . Of the two D-Ala-D-Lac ligase families, the one represented by the Leuconostoc mesenteroides ligase (LmDdl2) has a comparable omega loop, whereas the second, represented by the VanA and VanB ligases and the DdlM from the glycopeptide antibiotic producer Streptomyces toyocaensis, has a strikingly different sequence of residues for the putative omega loop. The gain of function to make the D-Ala-D-Lac depsipeptide is the key molecular switch that reprograms the VanA and VanB type VRE to produce a vancomycin-resistant cell wall.
E. coli DdlB as D-Ala-D-Ala ligase prototype
Until recently, the only available X-ray structure of a D-Ala-D-X ligase superfamily member has been that of the D-Ala-D-Ala ligase from E. coli (DdlB) with bound ADP and a phosphorylated D-Ala-D-Ala phosphinate transition-state inhibitor (Figure 4a,b) [19] . DdlB belongs to the ATP-grasp superfamily of enzymes that have an unusual nucleotide-binding fold [21] [22] [23] [24] . All of these ATP-grasp enzymes hydrolyze ATP to ADP and inorganic phosphate and ligate one substrate with a carboxylate to a second substrate with a primary amine, secondary amine, hydroxyl or thiol [25] . The catalytic mechanism of these enzymes is also thought to include formation of an Figure 5 ).
Structural alignment of DdlB with two other ATP-grasp proteins, E. coli glutathione synthetase and biotin carboxylase, revealed a similar binding site for ATP in a cleft formed by two structural elements, each containing two antiparallel β strands and a loop [22] . Despite only a 12% sequence identity between biotin carboxylase and glutathione synthetase, 127 Cα atoms superimpose with a root mean square deviation (rmsd) of only 1.64 Å [22] . Similarly, 101 Cα atoms of biotin carboxylase and DdlB superimpose with a rmsd of 1.91 Å. In addition, most of the amino acid residues that interact with ATP in DdlB are conserved in all ATP-grasp proteins. For example, Lys97 and Lys144 (DdlB numbering) are conserved in all sequences except for substitution by arginine in carbamoyl phosphate synthetases [25] . This sequence conservation of all ATP-grasp proteins and the conserved tertiary structure of three crystallized members support a common evolutionary ancestor for these enzymes.
On the basis of the crystal structure of DdlB, two loops close over the catalytic cavity, as observed in other ATP-grasp enzymes ( Figure 4b ) [19] . The first loop connects two β strands and contains Glu148-Gly-Ser-Ser-Val-Gly. This loop is part of a X-Gly-Ser-Ser-X-Gly motif, where position X is variable, that is conserved in all D-Ala-D-X ligases [17] . The second loop, called the omega loop, also connects β strands and forms a short helix consisting of amino acids 206-220 [19] .
The omega loop is believed to be flexible and exposed in the uncomplexed enzyme [30] . The hydroxyl groups of Ser150 and Ser151 of the first loop form three hydrogen bonds to the omega loop and help hold it in place ( Figure 4b ). Closing of the omega loop over the active site
Review Vancomycin resistance in enterococci Healy et al. R111 Table 1 Resistance to glycopeptide antibiotics in the three classes of vancomycin-resistant enterococci [ of DdlB is thought to be required for most of the interactions with ADP. The hydrogen-bond network of Glu15, Ser150 and Tyr216 also orients Lys215 for stabilization of γ-PO 3 transfer to D-Ala in subsite 1 (D-Ala 1 ; Figure 5b) . A solvent accessibility calculation shows that only 2% of the surface area of the enzyme bound ADP and D-Ala-D-Ala phosphinophosphate transition-state inhibitor is exposed, so the loops are expected to be effective in preventing hydrolysis of reactive intermediates (e.g. D-alanyl phosphate) by water [19] .
Kinetic analysis of purified DdlB revealed a k cat value of 1870 min -1 at pH 7.8 for D-Ala-D-Ala synthesis but no detectable D-Ala-D-Lac activity [18] . At pH 6.0, there is very low D-Ala-D-Lac ligase activity that is less than 10% of the dipeptide ligase activity and probably not physiologically significant, but this intrinsic activity could contribute to the possible evolution of D-Ala-D-Lac ligases from DdlB [31] . Electrostatic calculations [32] and the slight decrease in D-Ala K m2 values as pH increases [31] suggests that DdlB can utilize both the protonated and deprotonated forms (NH 3 + or NH 2 ) of D-Ala at subsite 2 (D-Ala 2 ) as substrates but may bind the deprotonated form, which is more abundant at high pH, with higher affinity. For D-Ala-D-Ala synthesis, DdlB binds Ala 1 in subsite 1 with high affinity (1 µM) but binds Ala 2 in subsite 2 with a 1000-fold weaker K m2 of 1.1 mM [18] . On the basis of the in vivo concentration of 0.5 mM D-Ala in exponentially growing E. coli, the rate of D-Ala-D-Ala formation in vivo could be limited by the possible failure to saturate subsite 2 of DdlB [33] .
VanA/B family
In contrast to the D-Ala-D-Ala ligase families, the VanA family synthesizes predominantly D-Ala-D-Lac by selectively activating D-lactate while discriminating against D-Ala 2 (Table 2 ) [17, 31] . Based on the pH profile of D-Ala-D-Ala synthesis, VanA only utilizes the deprotonated (NH 2 ) form of D-Ala 2 as a substrate [17, 31] . Thus, one mechanism that VanA uses to minimize the amount of D-Ala-D-Ala produced at physiological pH is to reject the protonated (NH 3 + ) form of D-Ala 2 that is predominantly present in solution (99.9% at pH 7.0). This result is in contrast to the electrostatic calculations [32] and weaker pH dependence of dipeptide synthesis by DdlB [31] and VanC2 (V.L.H., unpublished observations) that imply that DdlB and VanC2 can utilize both the protonated and deprotonated forms of amino acid substrates at subsite 2.
Because the pH profiles for His244→Ala and Arg242→Ala VanA mutants were less pH dependent and consisted of K m2 values that were 2-3-fold lower than those of wildtype VanA, His244 and Arg242 appeared partially responsible for the rejection of the protonated ( been transferred via one or more bacterial intermediates with a lower GC content to VRE, resulting in vanA and vanB with GC contents (45% and 48%, respectively) that are high for enterococcal genes. In addition the vanHAX gene cluster in VRE has the same orientation and gene alignment as that in S. toyocaensis [35, 36] . Alternatively, VanA and VanB may have evolved independently from other D-Ala-D-X family members.
Leuconostoc D-Ala-D-Lac ligase family
In addition to VRE, other gram-positive bacteria, such as the Leuconostoc ligase family, are intrinsically resistant to vancomycin because D-Ala-D-Lac is incorporated into their cell wall [37, 38] . The omega loop sequence for LmDdl2 is similar to that of DdlB, except for the presence of Phe261, which is required for D-Ala-D-Lac synthesis and corresponds to the Tyr216→Phe (Y216F) DdlB mutant with a gain of depsipeptide synthesis [20] . The recent X-ray structure of LmDdl2 suggests that the smaller size and greater hydrophobicity of the active site than that of DdlB contribute to the 75-fold greater selectivity for depsipeptide over dipeptide synthesis compared to Y216F DdlB ( [39] .
VanC family
In contrast to VanA and VanB classes of VRE, VanC-mediated resistance is predominantly chromosomal and constitutive [11, 40] . VanC2 from E. casseliflavus is a D-Ala-Ser ligase with no detectable D-Ala-D-Lac activity [41] . VanC2 has a 240-fold preference for D-serine over D-Ala 2 in subsite 2 (Table 3 ) [41, 42] . Modeling the structure of VanC2 on the basis of the X-ray structure of the D-Ala-D-Ala ligase DdlB [19] predicted that Arg322 and Phe250 could be responsible for the greater affinity of D-Ser in the second binding site of VanC2 [42] . This hypothesis was supported by mutating these residues in VanC2 to the corresponding residues in DdlB, resulting in a Phe250→Tyr/Arg322→Met VanC2 double mutant with reversed substrate specificity: the mutant retained D-Ala-D-Ala ligase activity but had negligible D-Ala-D-Ser activity ( 
Chemical mechanism of D-Ala-D-X ligases
The (Figure 8b ) has a change to phenylalanine, disrupting a hydrogen-bond network. This Tyr/Phe switch is one architectural element for dipeptide to depsipeptide switching because the E. coli DdlB F216Y mutant has a noticeable gain of D-Ala-D-Lac synthesis (Table 2 ) and the LmDdl2 F261Y loses the depsipeptide ligation activity [20] . VanA (Figure 8c ) uses His244 in this locale, oriented by Tyr315, suggesting a different mechanism from LmDdl2, which is a distinct family of D-Ala-D-X ligases ( Figure 3 ).
The second step in the reaction mechanism of these ligases is the capture of D-Ala 1 -P by the nucleophilic cosubstrate, D-Ala 2 , D-Ser or D-Lac, which must be deprotonated (from zwitterion to free amine form for D-Ala 2 and D-Ser; from alcohol to alkoxide for D-Lac) to engage in peptide or depsipeptide bond formation. Despite the X-ray structures, the identity of the catalytic base in these
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Figure 7
Comparison of vancomycin-resistance cassette in E. faecium to the orientation of the corresponding genes in the antibiotic producer S. toyocaensis [34] . steps is not resolved, and could, for example, be bound water, Asp257 or even the phosphate group of D-Ala 1 -P for DdlB [18] . For VanA, where only the minor, free base form of D-Ala 2 binds productively, a catalytic base may not be provided by the protein when it makes D-Ala-D-Ala [17] . 
Companion enzymes
The Ddl, VanA/B and VanC pathways all require two additional enzymes to make PG: an alanine racemase for generation of D-Ala as a D-Ala-D-X ligase substrate and an enzyme for adding the D-Ala-D-X dipeptide/depsipeptide product to a cytoplasmic PG precursor ( Figure 9 ). D-Ala is formed from conversion of L-Ala by alanine racemase. E. coli has two genes encoding alanine racemases: alr encodes a constitutive biosynthetic enzyme, while dadX encodes a catabolic enzyme that is inducible by D/L-Ala.
After synthesis, D-Ala-D-X is added to an UDP-N-acetylmuramic acid (UDP-MurNAc) tripeptide moiety by the enzyme MurF in an ATP-dependent mechanism [43] . Similar to the reaction catalyzed by the D-Ala-D-X ligases, this reaction probably involves γ-phosphate transfer to the UDP-MurNAc-tripeptide to form an acyl phosphate that is then attacked by the D-Ala-D-X peptide/depsipeptide, generating the UDP-MurNAc pentapeptide and inorganic phosphate. The UDP-MurNAc pentapeptide is subsequently modified by addition of a lipid carrier and N-acetylglucosamine to form the lipid-PP-disaccharidepentapeptide, which is translocated to the extracellular side of the cytoplasm for incorporation into the cell wall.
For the VanA and VanB classes of vancomycin resistance, the genes vanS, R, H and X are also required for resistance [5, 44] . From [42] .
Figure 9
Reactions catalyzed by alanine racemase and MurF in cell-wall biosynthesis [43, 62] . The partial negative charge of the phosphonate bridging oxygen is repelled by the negatively charged Glu181 sidechain and a mainchain carbonyl group of Tyr109; additionally, the bridging oxygen could form an intraligand hydrogen bond with the terminal amino group of the inhibitor, resulting in the loss of a hydrogen bond between the amino group of the inhibitor and the enzyme [49] .
VanS and VanR form a two-component regulatory system that senses vancomycin and regulates expression of the vanH, A and X genes ( Figure 11 ) [51] . VanS is a sensor kinase that undergoes autophosphorylation on a conserved histidine residue in its cytoplasmic domain and then phosphoryl transfer to an aspartate residue on the response regulator VanR, increasing the affinity of VanR for the promoter region of the vanH, A, and X triad by 500-fold [52] . VanS autophosphorylation is induced by vancomycin and teicoplanin in the VanA VRE phenotype but only by vancomycin in the VanB phenotype. VanC resistance is constitutive and thus does not seem to require VanS or VanR.
The VanC class of resistance also requires a membranebound serine racemase that has been recently isolated from E. gallinarum [53] . This pyridoxal 5′-phosphatedependent enzyme, VanT, racemizes L-Ser to the D-enantiomer for use by the VanC ligase to generate D-Ala-D-Ser.
Strategies and progress in combating VRE
Given the rapid spread of VRE in hospitals and the high mortality from such infections in immunocompromised patients, there has been great interest in finding antibiotics that will kill VRE. One approach has been to use the knowledge gained about the molecular logic of the cell wall reprogramming from vancomycin-sensitive to vancomycin-resistant bacteria to identify new targets. Clearly VanA is one, along with the associated enzymes VanH (the D-Lac dehydrogenase/pyruvate reductase) and VanX (the D-Ala-D-Ala dipeptidase). The vanHAX structural genes are controlled by a two-component sensor kinaseresponse regulator pair, VanS and VanR, so all five of these proteins are targets for inhibition of function and reversal of VRE. The phosphinates that cocrystallize are potent inhibitors of the D-Ala-D-X ligases in vitro [54] and there are reports of inhibitors of two-component sensor/ response regulators [55] , but to date no inhibitors of these five proteins have been reported that can gain access to the bacterial cytoplasm and have activity in vivo. A second approach has been to screen natural product and other compound libraries for efficacy against VRE. This strategy has revealed that hydrophobic derivatives of vancomycin family members, such as the N-(chlorobiphenyl)-chloroeremomycin LY333328, is about two logs more active than vancomycin against VRE [56] . Other peptide-based drugs that have efficacy against VRE are the quinuprustin/dalfoprustin combination Synercid [57] and the lipodepsipeptide ramiplanin [58] .
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Figure 10
Comparison of E. faecium and E. coli DdlB active sites with bound phosphinate inhibitor [19, 49] . From [50] . The D-Ala-D-X ligases remain an attractive target and as ATP-grasp proteins they share common structural elements with members of the protein kinase family fold [24] . There are large libraries of compounds that target ATP sites of protein kinases [59] that have yet to be evaluated systematically against the D-Ala-D-X ligases.
Figure 11
VanRS two-component system that activates transcription of vanHAX genes [51] . 
